NasdaqGS - Delayed Quote • USD
Gilead Sciences, Inc. (GILD)
At close: May 28 at 4:00 PM EDT
After hours: May 28 at 7:34 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 21 | 21 | 23 | 25 |
| Avg. Estimate | 1.59 | 1.73 | 3.75 | 7.15 |
| Low Estimate | 1.41 | 1.53 | 3.57 | 5.98 |
| High Estimate | 1.7 | 1.99 | 3.93 | 8.02 |
| Year Ago EPS | 1.34 | 2.29 | 6.28 | 3.75 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 19 | 18 | 26 | 26 |
| Avg. Estimate | 6.7B | 6.97B | 27.61B | 27.93B |
| Low Estimate | 6.31B | 6.67B | 27.26B | 27.22B |
| High Estimate | 7.01B | 7.25B | 28.14B | 28.94B |
| Year Ago Sales | 6.6B | 6.8B | 25.33B | 27.61B |
| Sales Growth (year/est) | 1.50% | 2.50% | 9.00% | 1.20% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | 1.64 | 1.92 | 1.64 | -1.49 |
| EPS Actual | 1.34 | 2.29 | 1.61 | -1.32 |
| Difference | -0.3 | 0.37 | -0.03 | 0.17 |
| Surprise % | -18.30% | 19.30% | -1.80% | 11.40% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 1.59 | 1.73 | 3.75 | 7.15 |
| 7 Days Ago | 1.59 | 1.73 | 3.75 | 7.14 |
| 30 Days Ago | 1.69 | 1.91 | 3.93 | 7.3 |
| 60 Days Ago | 1.71 | 1.93 | 7.09 | 7.43 |
| 90 Days Ago | 1.71 | 1.93 | 7.1 | 7.44 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | 1 | 1 |
| Up Last 30 Days | 2 | -- | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | GILD | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 18.70% | -- | -- | 7.90% |
| Next Qtr. | -24.50% | -- | -- | 10.20% |
| Current Year | -40.30% | -- | -- | 4.80% |
| Next Year | 90.70% | -- | -- | 12.50% |
| Next 5 Years (per annum) | 5.56% | -- | -- | 11.27% |
| Past 5 Years (per annum) | 1.66% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Barclays: Equal-Weight to Equal-Weight | 4/29/2024 |
| Maintains | TD Cowen: Buy to Buy | 4/26/2024 |
| Maintains | Morgan Stanley: Equal-Weight to Equal-Weight | 4/26/2024 |
| Maintains | RBC Capital: Sector Perform to Sector Perform | 4/26/2024 |
| Reiterates | Needham: Hold | 4/26/2024 |
| Upgrade | HSBC: Reduce to Hold | 4/24/2024 |
Related Tickers
BMY Bristol-Myers Squibb Company
40.49
-1.82%
AMGN Amgen Inc.
300.19
-1.85%
ABBV AbbVie Inc.
155.34
-1.10%
MRK Merck & Co., Inc.
126.09
-2.63%
JNJ Johnson & Johnson
144.38
-1.76%
BIIB Biogen Inc.
218.73
+0.42%
GSK GSK plc
44.24
-1.95%
PFE Pfizer Inc.
28.30
-2.01%
AZN AstraZeneca PLC
76.62
-2.44%
SNY Sanofi
47.94
-1.24%